GAMMA Investing LLC Has $104,000 Stake in Sarepta Therapeutics, Inc. (NASDAQ:SRPT)

GAMMA Investing LLC boosted its stake in Sarepta Therapeutics, Inc. (NASDAQ:SRPT) by 27.7% in the fourth quarter, according to its most recent filing with the Securities and Exchange Commission. The fund owned 854 shares of the biotechnology company’s stock after buying an additional 185 shares during the quarter. GAMMA Investing LLC’s holdings in Sarepta Therapeutics were worth $104,000 as of its most recent SEC filing.

A number of other institutional investors and hedge funds have also bought and sold shares of SRPT. Sunbelt Securities Inc. grew its stake in Sarepta Therapeutics by 446.2% in the 3rd quarter. Sunbelt Securities Inc. now owns 284 shares of the biotechnology company’s stock valued at $35,000 after purchasing an additional 232 shares during the period. Huntington National Bank grew its stake in shares of Sarepta Therapeutics by 150.9% during the 3rd quarter. Huntington National Bank now owns 291 shares of the biotechnology company’s stock worth $36,000 after acquiring an additional 175 shares during the period. Nkcfo LLC bought a new position in shares of Sarepta Therapeutics during the 2nd quarter worth $43,000. UMB Bank n.a. grew its stake in shares of Sarepta Therapeutics by 105.9% during the 3rd quarter. UMB Bank n.a. now owns 383 shares of the biotechnology company’s stock worth $48,000 after acquiring an additional 197 shares during the period. Finally, Values First Advisors Inc. bought a new position in shares of Sarepta Therapeutics during the 3rd quarter worth $59,000. 86.68% of the stock is owned by hedge funds and other institutional investors.

Wall Street Analysts Forecast Growth

Several research firms have recently weighed in on SRPT. Piper Sandler cut their price target on Sarepta Therapeutics from $200.00 to $182.00 and set an “overweight” rating for the company in a research note on Wednesday, November 27th. Robert W. Baird dropped their price objective on Sarepta Therapeutics from $200.00 to $193.00 and set an “outperform” rating on the stock in a report on Thursday, November 7th. Cantor Fitzgerald raised Sarepta Therapeutics from a “neutral” rating to an “overweight” rating and increased their price objective for the stock from $152.00 to $167.00 in a report on Thursday, November 7th. StockNews.com cut Sarepta Therapeutics from a “buy” rating to a “hold” rating in a report on Wednesday, November 20th. Finally, Jefferies Financial Group began coverage on Sarepta Therapeutics in a report on Monday, October 21st. They set a “buy” rating and a $165.00 price objective on the stock. One analyst has rated the stock with a sell rating, two have given a hold rating, nineteen have assigned a buy rating and one has assigned a strong buy rating to the stock. According to data from MarketBeat.com, Sarepta Therapeutics presently has an average rating of “Moderate Buy” and an average price target of $178.71.

Insider Buying and Selling

In related news, Director Hans Lennart Rudolf Wigzell sold 10,500 shares of Sarepta Therapeutics stock in a transaction that occurred on Thursday, December 12th. The stock was sold at an average price of $124.84, for a total transaction of $1,310,820.00. Following the sale, the director now directly owns 22,840 shares in the company, valued at $2,851,345.60. The trade was a 31.49 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is available through this hyperlink. Also, Director Kathryn Jean Boor sold 1,636 shares of Sarepta Therapeutics stock in a transaction that occurred on Thursday, December 5th. The shares were sold at an average price of $125.55, for a total value of $205,399.80. Following the sale, the director now owns 5,880 shares in the company, valued at $738,234. This represents a 21.77 % decrease in their ownership of the stock. The disclosure for this sale can be found here. 7.70% of the stock is owned by corporate insiders.

Sarepta Therapeutics Price Performance

SRPT opened at $124.79 on Friday. The stock’s 50 day simple moving average is $122.11 and its 200 day simple moving average is $131.33. The company has a debt-to-equity ratio of 0.93, a current ratio of 3.84 and a quick ratio of 3.03. Sarepta Therapeutics, Inc. has a 1 year low of $102.15 and a 1 year high of $173.25. The firm has a market cap of $11.92 billion, a price-to-earnings ratio of 99.83 and a beta of 0.77.

Sarepta Therapeutics Company Profile

Sarepta Therapeutics, Inc, a commercial-stage biopharmaceutical company, focuses on the discovery and development of RNA-targeted therapeutics, gene therapies, and other genetic therapeutic modalities for the treatment of rare diseases. It offers EXONDYS 51 injection to treat duchenne muscular dystrophy (duchenne) in patients with confirmed mutation of the dystrophin gene that is amenable to exon 51 skipping; VYONDYS 53 for the treatment of duchenne in patients with confirmed mutation of the dystrophin gene that is amenable to exon 53 skipping; AMONDYS 45 for the treatment of duchenne in patients with confirmed mutation of the dystrophin gene; and ELEVIDYS, an adeno-associated virus based gene therapy for the treatment of ambulatory pediatric patients aged 4 through 5 years with duchenne with a confirmed mutation in the duchenne gene.